Survival and mutational differences based on <i>ESR1</i> and <i>ESR2</i> expression in non-small cell lung cancer (NSCLC).
Robert Hsu(University of Southern California), Jorge J. Nieva(University of Southern California), Hirva Mamdani(Wayne State University), Andrew Elliott(Caris Life Sciences (United States)), Alexis Leyba(University of Southern California), Evanthia T. Roussos Torres(University of Southern California), Ari M. Vanderwalde(West Cancer Center), Denaly Chen(University of Southern California), Harris Benjamin Krause(Caris Life Sciences (United States)), Stephen V. Liu(Georgetown University), Wendy Cozen(University of Southern California), C. Patrick(Penn State Milton S. Hershey Medical Center), Misako Nagasaka(University of California, Irvine), Gilberto Lopes(University of Miami), Hossein Borghaei(Fox Chase Cancer Center)
Cited by 2
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k